Carlos L. Arteaga, MD, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Carlos L. Arteaga, MD
Advertisement
Articles by Carlos L. Arteaga, MD
Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Results and Impact of the Follow-Up of the NeoALTTO TrialPublished: January 21st 2014 | Updated:
Comparing Data for Capecitabine After Neoadjuvant Chemotherapy in TNBCPublished: January 16th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
